TQC3927
/ Sino Biopharm
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
February 20, 2025
A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
December 02, 2024
A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease
(clinicaltrials.gov)
- P1 | N=48 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
October 29, 2024
A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=60 | Completed | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Completed | Trial completion date: Feb 2025 ➔ Aug 2024 | Trial primary completion date: Dec 2024 ➔ Aug 2024
Trial completion • Trial completion date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
May 10, 2024
A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=60 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 4
Of
4
Go to page
1